Search
galcanezumab (Emgality)
Indications:
- migraine
- episodic cluster headache [2]
Dosage:
- monthly injection [1]
- loading dose of 240 mg loading dose (administered as two consecutive injections of 120 mg each), followed by monthly doses of 120 mg [2]
Adverse effects:
- injection site reactions (most common)
- serious & prolonged hypersensitivity reactions can occur days after injection [2]
Mechanism of action:
- humanized monoclonal Ab against calcitonin gene-related peptide
Notes:
- annual cost of treatment is $6900 (2019) [1,2]
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
calcitonin gene-related peptide (CGRP) inhibitor
pharmaceutical monoclonal antibody
References
- Orciari Herman A, Sadoughi S, Sofair A
FDA Approves New Migraine Drug
Physician's First Watch, Oct 1, 2018
David G. Fairchild, MD, MPH, Editor-in-Chief
Massachusetts Medical Society
http://www.jwatch.org
- Lilly's Emgality (galcanezumab-gnlm) Receives U.S. FDA
Approval for the Preventive Treatment of Migraine in Adults.
News Release. Sept 27, 2018
https://investor.lilly.com/news-releases/news-release-details/lillys-emgalitytm-galcanezumab-gnlm-receives-us-fda-approval
- FDA News Release. June 4, 2019
FDA approves first treatment for episodic cluster headache that
reduces the frequency of attacks.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-episodic-cluster-headache-reduces-frequency-attacks
- HIGHLIGHTS OF PRESCRIBING INFORMATION
EMGALITY (galcanezumab-gnlm) injection, for subcutaneous use
http://pi.lilly.com/us/emgality-uspi.pdf